Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 66.89 (+2.06%)
Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update

--Advancing SAGE-217 into Part B open-label Phase 2 trial in Parkinson's disease based on initial activity signal

SAGE : 66.89 (+2.06%)
Investor Network: SAGE Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 9, 2017 / SAGE Therapeutics, Inc. (NASDAQ: SAGE) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 4:30 PM Eastern Time.

SAGE : 66.89 (+2.06%)
How These Biotech Stocks are Faring? -- Cymabay Therapeutics, Benitec Biopharma, Sage Therapeutics, and Catalyst Biosciences

On Tuesday, April 25, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Tuesday's trading session in bullish...

BNTC : 2.37 (+0.85%)
CBAY : 3.91 (unch)
SAGE : 66.89 (+2.06%)
CBIO : 3.90 (-3.23%)
BNIKF : 0.1392 (+3.88%)
Sage Therapeutics to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 66.89 (+2.06%)
Sage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the appointment...

SAGE : 66.89 (+2.06%)
5 Drug Stocks for Your Portfolio this World Health Day

With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.

JNJ : 127.26 (+0.20%)
AGN : 219.52 (+0.18%)
SAGE : 66.89 (+2.06%)
ALKS : 58.32 (+0.71%)
VTGN : 1.99 (+1.02%)
First Week of November 17th Options Trading For Sage Therapeutics (SAGE)

Investors in Sage Therapeutics Inc saw new options become available this week, for the November 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the...

SAGE : 66.89 (+2.06%)
Pershing Gold to Present at 2017 European Gold Forum

Pershing Gold Corporation (NASDAQ:PGLC) (TSX: PGLC) (FWB:7PG1) ("Pershing Gold" or the "Company"), the emerging Nevada gold producer advancing the Relief Canyon Mine, today announced that Stephen Alfers...

PGLC.TO : 3.93 (-1.75%)
SAGE : 66.89 (+2.06%)
PGLC : 2.88 (-0.69%)
Pershing Gold to Present at 2017 European Gold Forum

Pershing Gold Corporation (NASDAQ:PGLC) (TSX: PGLC) (FWB:7PG1) ("Pershing Gold" or the "Company"), the emerging Nevada gold producer advancing the Relief Canyon Mine, today announced that Stephen Alfers...

PGLC.TO : 3.93 (-1.75%)
SAGE : 66.89 (+2.06%)
PGLC : 2.88 (-0.69%)
Are Options Traders Betting on a Big Move in Sage Therapeutics (SAGE) Stock?

Options Traders are Betting on a Big Move in Sage Therapeutics (SAGE) Stock on the back of its huge implied volatility.

SAGE : 66.89 (+2.06%)
Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma

On Thursday, March 23, 2017, the NASDAQ Composite ended the trading session at 5,817.69, down 0.07%; the Dow Jones Industrial Average edged 0.02% lower, to finish at 20,656.58; and the S&P 500 closed at...

BNTC : 2.37 (+0.85%)
BDSI : 2.35 (-4.08%)
SAGE : 66.89 (+2.06%)
OGXI : 0.36 (+2.86%)
BNIKF : 0.1392 (+3.88%)
Option Trades: Covered Call reports for American Airlines, Alnylam Pharmaceuticals, The Kroger Co, Resolute Energy Corporation and Sage Therapeutics include trade ideas that offer returns of 25% or more!

InvestorsObserver issues critical PriceWatch Alerts for AAL, ALNY, KR, REN, and SAGE.

KR : 29.28 (+0.17%)
ALNY : 73.93 (+3.15%)
REN : 42.71 (-2.93%)
SAGE : 66.89 (+2.06%)
AAL : 46.21 (+2.19%)
Blog Coverage La Jolla's Lead Product Candidate LJPC-501 Posts Positive Phase-III Trial Results

Upcoming AWS Coverage on Sage Therapeutics Post-Earnings Results

LJPC : 33.70 (-0.88%)
SAGE : 66.89 (+2.06%)
Sage Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

--Phase 2 placebo-controlled study of SAGE-217 in major depressive disorder expected to begin in 1H 2017

SAGE : 66.89 (+2.06%)
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More

The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.

LGND : 113.44 (-0.33%)
BMRN : 90.49 (+1.41%)
ZTS : 60.31 (unch)
SAGE : 66.89 (+2.06%)
TEVA : 29.44 (-1.47%)
ICPT : 113.72 (+1.29%)
ALXN : 115.42 (+1.39%)
Sage Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, February 23, 2017

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 66.89 (+2.06%)
Sage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced encouraging...

SAGE : 66.89 (+2.06%)
Sage Therapeutics to Participate in Upcoming February Investor Conferences

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 66.89 (+2.06%)
Noteworthy Thursday Option Activity: SAGE, JCP, NSP

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sage Therapeutics Inc , where a total volume of 4,498 contracts has been traded thus...

SAGE : 66.89 (+2.06%)

Van Meerten Stock Picks

5 Large Cap Stocks for Momentum Investors
Today I wanted to find 5 Large Cap stocks that would be of inter st for Momentum Investors.
AMAT +0.65 , ESS +0.04 , BF.B +3.99 , CTSH +0.37 , EA +0.75
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Jun E-mini S&Ps ( ESM17 +0.07%) this morning are up +0.01% and European stocks are down -0.33% . U.S. equities ae being led higher by strength in energy producing stocks as Jul WTI crude oil ( CLN17 +0.79%) climbs... Read More

Chart of the Day

Veeva Systems (VEEV) is the Barchart Chart of the Day. The Internet software company has a Trend Spotter buy signal, a Weighted Alpha of 100.07+ and gained 113.11% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures settled 2 1/2 to 2 3/4 cents higher in the front months on Monday. The USDA reported 1.144 MMT of corn was inspected for export during the week ending May 18. That is down 19.44% from a week ago but just 2.49% lower than the same time la...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.